BeyondSpring (NASDAQ:BYSI) Shares Up 0% – Time to Buy?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price traded up 0% during trading on Tuesday . The stock traded as high as $0.7556 and last traded at $0.7403. Approximately 15,701 shares changed hands during trading, a decline of 84% from the average session volume of 96,180 shares. The stock had previously closed at $0.74.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded BeyondSpring from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

BeyondSpring Price Performance

The firm’s 50-day moving average price is $0.86 and its 200-day moving average price is $1.35. The company has a market cap of $30.44 million, a price-to-earnings ratio of -6.17 and a beta of 0.06.

BeyondSpring (NASDAQ:BYSI) last posted its earnings results on Friday, August 14th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.52.

BeyondSpring Company Profile

BeyondSpring Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a selective immunomodulating microtubule-destabilizing agent designed to stimulate the immune system while affecting tumor-cell biology.

BeyondSpring has evaluated plinabulin for the prevention of chemotherapy-induced neutropenia, a potentially serious complication of cancer treatment, and for use in combination with other therapies in oncology, including treatment approaches for non-small cell lung cancer.